fda warning compounding semaglutide october 2025 Warns Against Compounded for Diabetes, Weight Loss Hims and Hers warns investors

But Healey urged commissioners to seriously consider the recommendation to scrap coverage for GLP-1 drugs for weight loss

Archived from the original on 2 February 2025

The scale may not move dramatically at first because AOD-9604 targets fat specifically, and improvements may show up in measurements and mirror changes before the scale reflects them

Key findings from the Phase 2 trial included: Dose-dependent reductions in body weight across all active treatment arms Significant improvements in waist circumference, a key marker of visceral adiposity Reductions in fasting insulin levels and HbA1c Improvements in lipid profiles, including triglycerides Phase 3 trials are currently ongoing and are expected to include larger, more diverse populations with more granular subgroup analyses, including sex-specific data

Further, these treatments require medical supervision to monitor progress and address any side effects